Shanghai Haishun New Pharmaceutical Packaging Co Ltd
SZSE:300501
Shanghai Haishun New Pharmaceutical Packaging Co Ltd
Income from Continuing Operations
Shanghai Haishun New Pharmaceutical Packaging Co Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
S
|
Shanghai Haishun New Pharmaceutical Packaging Co Ltd
SZSE:300501
|
Income from Continuing Operations
¥119.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
C
|
China Hongqiao Group Ltd
HKEX:1378
|
Income from Continuing Operations
¥12.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
Shandong Nanshan Aluminium Co Ltd
SSE:600219
|
Income from Continuing Operations
¥4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
21%
|
CAGR 10-Years
16%
|
|
A
|
Aluminum Corporation of China Ltd
SSE:601600
|
Income from Continuing Operations
¥12.6B
|
CAGR 3-Years
100%
|
CAGR 5-Years
52%
|
CAGR 10-Years
33%
|
Yunnan Aluminium Co Ltd
SZSE:000807
|
Income from Continuing Operations
¥4.7B
|
CAGR 3-Years
56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tianshan Aluminum Group Co Ltd
SZSE:002532
|
Income from Continuing Operations
¥2.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
79%
|
CAGR 10-Years
36%
|
See Also
What is Shanghai Haishun New Pharmaceutical Packaging Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
119.9m
CNY
Based on the financial report for Sep 30, 2023, Shanghai Haishun New Pharmaceutical Packaging Co Ltd's Income from Continuing Operations amounts to 119.9m CNY.
What is Shanghai Haishun New Pharmaceutical Packaging Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
12%
Over the last year, the Income from Continuing Operations growth was 4%. The average annual Income from Continuing Operations growth rates for Shanghai Haishun New Pharmaceutical Packaging Co Ltd have been 8% over the past three years , 12% over the past five years .